EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME
Top Cited Papers
- 1 March 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurosurgery
- Vol. 62 (3), 564-576
- https://doi.org/10.1227/01.neu.0000317304.31579.17
Abstract
The influence of the degree of resection on survival in patients with glioblastoma multiforme is still under discussion. The highly controlled 5-aminolevulinic acid study provided a unique platform for addressing this question as a result of the high frequency of "complete" resections, as revealed by postoperative magnetic resonance imaging scans achieved by fluorescence-guided resection and homogeneous patient characteristics. Two hundred forty-three patients with glioblastoma multiforme per protocol from the 5-aminolevulinic acid study were analyzed. Patients with complete and incomplete resections as revealed by early magnetic resonance imaging scans were compared. Prognostic factors that might cause bias regarding resection and influence survival (e.g., tumor size, edema, midline shift, location, age, Karnofsky Performance Scale score, National Institutes of Health Stroke Scale score) were used for analysis of overall survival. Time to reintervention (chemotherapy, reoperation) was analyzed further to exclude bias regarding second-line therapies. Treatment bias was identified in patients with complete (n = 122) compared with incomplete resection (n = 121), i.e., younger age and less frequent eloquent tumor location. Other factors, foremost preoperative tumor size, were identical. Patients without residual tumor survived longer (16.7 versus 11.8 mo, P < 0.0001). In multivariate analysis, only residual tumor, age, and Karnofsky Performance Scale score were significantly prognostic. To account for distribution bias, patients were stratified for age (>60 or <or=60 yr) and eloquent location. Survival advantages from complete resection remained significant within subgroups, and age/eloquent location were no longer unevenly distributed. Reinterventions occurred marginally earlier in patients with residual tumor (6.7 versus 9.5 mo, P = 0.0582). Treatment bias was demonstrated regarding resection and second-line therapies. However, bias and imbalances were controllable in the cohorts available from the 5-aminolevulinic acid study so that the present data now provide Level 2b evidence (Oxford Centre for Evidence-based Medicine) that survival depends on complete resection of enhancing tumor in glioblastoma multiforme.Keywords
This publication has 16 references indexed in Scilit:
- Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trialThe Lancet Oncology, 2006
- 483 ORAL Impact of extent of resection on overall survival in newly-diagnosed glioblastoma after chemo-irradiation with temozolomide: further analysis of EORTC study 26981European Journal of Cancer Supplements, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- Debulking or biopsy of malignant glioma in elderly people – a randomised studyActa Neurochirurgica, 2003
- A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survivalJournal of Neurosurgery, 2001
- Radiation response and survival time in patients with glioblastoma multiformeJournal of Neurosurgery, 1996
- Ensuring reliability of outcome measures in multicenter clinical trials of treatments for acute ischemic stroke. The program developed for the Trial of Org 10172 in Acute Stroke Treatment (TOAST).Stroke, 1994
- Serial assessment of acute stroke using the NIH Stroke Scale.Stroke, 1994
- The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients.Journal of Neurology, Neurosurgery & Psychiatry, 1990
- Interrater Reliability of the NIH Stroke ScaleArchives of Neurology, 1989